HL301
Phase 2Small molecule
HL301 is one of 65 small molecule programs targeting Acute bronchitis. It is currently in Phase 2.
3
Indications
4
Total Trials
0
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1PORTRAZZA
Eli LillyPreclinical
Lenvima
EisaiPreclinical
Imjudo
AstraZenecaPreclinical
Vizimpro
PfizerPreclinical
Gilotrif
Boehringer IngelheimPreclinical
HL301
HHanlim Pharm. Co., Ltd.
Phase 2
Ofev
Boehringer IngelheimPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute bronchitis2 trials
Non-Small Cell Lung Cancer1 trial
Chronic Bronchitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HL301. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHanlim Pharm. Co., Ltd.